Should patients with ALL undergo HSCT after CAR T-cell therapy? – Healio
|
Should patients with ALL undergo HSCT after CAR T-cell therapy?
Healio CAR T-cell therapies for ALL hold great promise, yielding remission rates of up to 90% for relapsed/refractory patients. However, the durability of these responses remains uncertain, particularly in adults, as follow-up data are limited for most … |
